Mercredi, 15 Juillet 2020
Dernières nouvelles
Principale » $0.87 EPS Expected for Edwards Lifesciences Corp

$0.87 EPS Expected for Edwards Lifesciences Corp

01 Octobre 2017

Sectoral Asset Management Inc cut its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 20.0% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. Edwards Lifesciences Corporation accounts for approximately 2.1% of Sectoral Asset Management Inc's holdings, making the stock its 21st largest position. Toronto Dominion Bank now owns 71,106 shares of the medical research company's stock valued at $8,406,000 after acquiring an additional 13,747 shares during the last quarter.

A number of other institutional investors have also modified their holdings of EW. Finally, Advisory Services Network LLC boosted its holdings in Edwards Lifesciences Corporation by 0.9% in the second quarter. Quadrant Capital Group LLC raised its position in Edwards Lifesciences Corp by 3.5% in the first quarter. Insiders have sold 176,901 shares of company stock valued at $20,191,196 over the last ninety days. Quadrant Capital Group LLC now owns 1,209 shares of the medical research company's stock worth $109,000 after buying an additional 41 shares during the last quarter. LLC boosted its holdings in Edwards Lifesciences Corporation by 58.4% in the second quarter. Municipal Employees Retirement System of MI now owns 6,700 shares of the medical research company's stock worth $808,000 after buying an additional 20 shares during the last quarter.

Edwards Lifesciences Corporation (NYSE:EW) was down -0.46% (-$0.5) to $108.87 and showed a volume of 1.06 mln shares.

The analysts offering 12 month price targets for Edwards Lifesciences Corporation have a median target of $132, with a high estimate of $155 and a low estimate of $94. About 861,690 shares traded or 45.37% up from the average. The last stock price is up -0.05% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has increased 0.04% over the same time period. The firm has a market capitalization of $23.08 billion, a P/E ratio of 33.15 and a beta of 0.64.

Penn State stays at No
Mississippi State, which was No. 24 in last week's poll, dropped out of the rankings altogether following the loss. The Big 12 was also represented by TCU (No. 8), Oklahoma State (15) and West Virginia (23) in the AP poll.

Edwards Lifesciences Corporation (NYSE:EW) last posted its quarterly earnings data on Wednesday, July 26th. Analysts forecast that Edwards Lifesciences Corporation will post $3.78 earnings per share for the current fiscal year. The business's quarterly revenue was up 10.9% on a year-over-year basis. A month ago, they told us to expect earnings of US$0.91 per share while three months ago their EPS consensus estimate was US$0.89. If you are reading this article on another website, it was illegally stolen and reposted in violation of worldwide trademark & copyright laws.

A total of 22 equity analysts have released a ratings update on EW. zero equity analysts rating the company a strong buy, zero equity analysts rating the company a buy, zero equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $117.68. Royal Bank Of Canada reaffirmed a "buy" rating and issued a $130.00 price target on shares of Edwards Lifesciences Corporation in a research note on Friday, September 1st. Cowen and Company reiterated an "outperform" rating and issued a $120.00 price objective on shares of Edwards Lifesciences Corp in a research note on Tuesday, March 28th. Edwards Lifesciences Corporation now has a consensus rating of "Buy" and an average price target of $120.75. Seven equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of "Buy" and an average price target of $118.34. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 25,000 shares of the company's stock in a transaction dated Friday, August 4th. The disclosure for this purchase can be found here. Currently, 210.57 million total shares are owned by the public and among those 209.79 million shares have been available to trade.

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and fix products used to replace or fix a patient's diseased or defective heart valve. The Firm is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Want to see what other hedge funds are holding EW?